• Something wrong with this record ?

Structure-Activity Relationship of (18)F-Labeled Phosphoramidate Peptidomimetic Prostate-Specific Membrane Antigen (PSMA)-Targeted Inhibitor Analogues for PET Imaging of Prostate Cancer

S. Dannoon, T. Ganguly, H. Cahaya, JJ. Geruntho, MS. Galliher, SK. Beyer, CJ. Choy, MR. Hopkins, M. Regan, JE. Blecha, L. Skultetyova, CR. Drake, S. Jivan, C. Barinka, EF. Jones, CE. Berkman, HF. VanBrocklin,

. 2016 ; 59 (12) : 5684-94. [pub] 20160613

Language English Country United States

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc17023954

A series of phosphoramidate-based prostate specific membrane antigen (PSMA) inhibitors of increasing lipophilicity were synthesized (4, 5, and 6), and their fluorine-18 analogs were evaluated for use as positron emission tomography (PET) imaging agents for prostate cancer. To gain insight into their modes of binding, they were also cocrystallized with the extracellular domain of PSMA. All analogs exhibited irreversible binding to PSMA with IC50 values ranging from 0.4 to 1.3 nM. In vitro assays showed binding and rapid internalization (80-95%, 2 h) of the radiolabeled ligands in PSMA(+) cells. In vivo distribution demonstrated significant uptake in CWR22Rv1 (PSMA(+)) tumor, with tumor to blood ratios of 25.6:1, 63.6:1, and 69.6:1 for [(18)F]4, [(18)F]5, and [(18)F]6, respectively, at 2 h postinjection. Installation of aminohexanoic acid (AH) linkers in the phosphoramidate scaffold improved their PSMA binding and inhibition and was critical for achieving suitable in vivo imaging properties, positioning [(18)F]5 and [(18)F]6 as favorable candidates for future prostate cancer imaging clinical trials.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17023954
003      
CZ-PrNML
005      
20170720122402.0
007      
ta
008      
170720s2016 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1021/acs.jmedchem.5b01850 $2 doi
035    __
$a (PubMed)27228467
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Dannoon, Shorouk $u Department of Radiology and Biomedical Imaging, University of California-San Francisco , 185 Berry Street, San Francisco, California 94107, United States.
245    10
$a Structure-Activity Relationship of (18)F-Labeled Phosphoramidate Peptidomimetic Prostate-Specific Membrane Antigen (PSMA)-Targeted Inhibitor Analogues for PET Imaging of Prostate Cancer / $c S. Dannoon, T. Ganguly, H. Cahaya, JJ. Geruntho, MS. Galliher, SK. Beyer, CJ. Choy, MR. Hopkins, M. Regan, JE. Blecha, L. Skultetyova, CR. Drake, S. Jivan, C. Barinka, EF. Jones, CE. Berkman, HF. VanBrocklin,
520    9_
$a A series of phosphoramidate-based prostate specific membrane antigen (PSMA) inhibitors of increasing lipophilicity were synthesized (4, 5, and 6), and their fluorine-18 analogs were evaluated for use as positron emission tomography (PET) imaging agents for prostate cancer. To gain insight into their modes of binding, they were also cocrystallized with the extracellular domain of PSMA. All analogs exhibited irreversible binding to PSMA with IC50 values ranging from 0.4 to 1.3 nM. In vitro assays showed binding and rapid internalization (80-95%, 2 h) of the radiolabeled ligands in PSMA(+) cells. In vivo distribution demonstrated significant uptake in CWR22Rv1 (PSMA(+)) tumor, with tumor to blood ratios of 25.6:1, 63.6:1, and 69.6:1 for [(18)F]4, [(18)F]5, and [(18)F]6, respectively, at 2 h postinjection. Installation of aminohexanoic acid (AH) linkers in the phosphoramidate scaffold improved their PSMA binding and inhibition and was critical for achieving suitable in vivo imaging properties, positioning [(18)F]5 and [(18)F]6 as favorable candidates for future prostate cancer imaging clinical trials.
650    _2
$a amidy $x chemická syntéza $x chemie $x farmakologie $7 D000577
650    _2
$a zvířata $7 D000818
650    _2
$a antigeny povrchové $7 D000954
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a radioizotopy fluoru $7 D005462
650    _2
$a glutamátkarboxypeptidasa II $x antagonisté a inhibitory $7 D043425
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a myši $7 D051379
650    _2
$a myši nahé $7 D008819
650    _2
$a molekulární modely $7 D008958
650    _2
$a molekulární struktura $7 D015394
650    _2
$a experimentální nádory $x diagnostické zobrazování $7 D009374
650    _2
$a peptidomimetika $x chemická syntéza $x chemie $x farmakologie $7 D057786
650    _2
$a kyseliny fosforečné $x chemická syntéza $x chemie $x farmakologie $7 D010756
650    12
$a pozitronová emisní tomografie $7 D049268
650    _2
$a nádory prostaty $x diagnostické zobrazování $7 D011471
650    _2
$a vztahy mezi strukturou a aktivitou $7 D013329
650    _2
$a nádorové buňky kultivované $7 D014407
655    _2
$a časopisecké články $7 D016428
700    1_
$a Ganguly, Tanushree $u Department of Chemistry, Washington State University , Pullman, Washington 99164-4630, United States.
700    1_
$a Cahaya, Hendry $u Department of Radiology and Biomedical Imaging, University of California-San Francisco , 185 Berry Street, San Francisco, California 94107, United States.
700    1_
$a Geruntho, Jonathan J $u Department of Chemistry, Washington State University , Pullman, Washington 99164-4630, United States.
700    1_
$a Galliher, Matthew S $u Department of Chemistry, Washington State University , Pullman, Washington 99164-4630, United States.
700    1_
$a Beyer, Sophia K $u Department of Chemistry, Washington State University , Pullman, Washington 99164-4630, United States.
700    1_
$a Choy, Cindy J $u Department of Chemistry, Washington State University , Pullman, Washington 99164-4630, United States.
700    1_
$a Hopkins, Mark R $u Department of Chemistry, Washington State University , Pullman, Washington 99164-4630, United States.
700    1_
$a Regan, Melanie $u Department of Radiology and Biomedical Imaging, University of California-San Francisco , 185 Berry Street, San Francisco, California 94107, United States.
700    1_
$a Blecha, Joseph E $u Department of Radiology and Biomedical Imaging, University of California-San Francisco , 185 Berry Street, San Francisco, California 94107, United States.
700    1_
$a Skultetyova, Lubica $u Institute of Biotechnology , 252 50 Prague, Czech Republic.
700    1_
$a Drake, Christopher R $u Department of Radiology and Biomedical Imaging, University of California-San Francisco , 185 Berry Street, San Francisco, California 94107, United States.
700    1_
$a Jivan, Salma $u Department of Radiology and Biomedical Imaging, University of California-San Francisco , 185 Berry Street, San Francisco, California 94107, United States.
700    1_
$a Barinka, Cyril $u Institute of Biotechnology , 252 50 Prague, Czech Republic.
700    1_
$a Jones, Ella F $u Department of Radiology and Biomedical Imaging, University of California-San Francisco , 185 Berry Street, San Francisco, California 94107, United States.
700    1_
$a Berkman, Clifford E $u Department of Chemistry, Washington State University , Pullman, Washington 99164-4630, United States. Cancer Targeted Technology , Woodinville, Washington 98072, United States.
700    1_
$a VanBrocklin, Henry F $u Department of Radiology and Biomedical Imaging, University of California-San Francisco , 185 Berry Street, San Francisco, California 94107, United States.
773    0_
$w MED00010049 $t Journal of medicinal chemistry $x 1520-4804 $g Roč. 59, č. 12 (2016), s. 5684-94
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27228467 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170720 $b ABA008
991    __
$a 20170720122854 $b ABA008
999    __
$a ok $b bmc $g 1239635 $s 984867
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 59 $c 12 $d 5684-94 $e 20160613 $i 1520-4804 $m Journal of medicinal chemistry $n J Med Chem $x MED00010049
LZP    __
$a Pubmed-20170720
Back

Find record

Citation metrics

Archiving options